Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI

NCT04954599 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.

NCT NCT04954599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04954599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI
Lead sponsor
Maastricht University Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 30, 2023
Completion date
May 31, 2027
Enrollment
126 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific